Skip to main content

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

Active, not recruiting · Phase 1 · NCT05527184

Conditions: Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cervical Cancer

At a glance

Research payments reported, 2025
$1.4M
U.S. investigators named
33
Sites paid
45
Planned or actual enrollment
256

About the trial

Sponsor
AbbVie
Tested
IMGN151 (drug)
Dates
Started 2023-01-11; completion 2027-02
Results posted
Not yet

IIMGN151-1001 is a Phase 1, first in human, open-label dose-escalation, optimization, and expansion study designed to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of IMGN151 in adult participants with recurrent endometrial cancer; recurrent, high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers; or recurrent cervical cancers. All participants will be, in the opinion of the investigator, appropriate for nonplatinum single-agent therapy for their next line of therapy.

From ClinicalTrials.gov, last updated 2026-02-20. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $1.4M in research payments for this study in 2025 (146 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.